#United States #Los Angeles #Life Sciences #AWS #Agilisium

Agilisium's Major Recognition by AWS

Agilisium, a prominent player in data innovation for the Life Sciences sector, proudly announces its recognition by Amazon Web Services (AWS) as one of only 13 global partners possessing both Generative AI and Life Sciences Consulting competencies. This accolade highlights Agilisium's advanced technical capabilities along with its deep expertise in transforming business operations while delivering enduring value to clients.

The Impact of Generative AI in Life Sciences

In the rapidly changing landscape of the Life Sciences industry, Agilisium stands out with its innovative Generative AI Advisory Program (GAAP). This program is designed to assist organizations in refining their strategic approach while assuring measurable impacts across their entire value chain. Noteworthy implementations of Generative AI involve drafting research papers from clinical study reports, conducting smart assessments based on biomarkers, optimizing supply chain logistics, and improving both omnichannel and healthcare professional (HCP) engagements.

Agilisium utilizes more than 20 Generative AI solutions that are powered by AWS’s advanced services to enhance the Life Sciences value chain significantly. These solutions demonstrate not just technical capabilities but also a commitment to ensuring better patient outcomes and accelerating drug discoveries across the sector.

A Word from Agilisium's Leadership

Raj Babu, Founder and CEO of Agilisium, emphasized the importance of this recognition: "We are thrilled that AWS recognizes our ongoing investments and the accomplishments we have achieved with over two dozen Generative AI solutions targeting the Life Sciences industry. Solutions such as Gene Inspector, Drug Watch, and MLR Review empower our clients to accelerate discoveries, improve patient outcomes, and make informed decisions. This acknowledgement reinforces our commitment to providing scalable, future-ready AI solutions shaping the next era in the Life Sciences realm."

Agilisium's Pioneering Role in Life Sciences

As one of the leading Data Innovation Partners in Life Sciences, Agilisium excels in delivering groundbreaking solutions that drive transformative change by merging strong domain expertise with data analytics, cloud services, Generative AI, and advanced analytical capabilities. Collaborations with major pharma and biotech companies allow Agilisium to uncover data-driven insights and develop innovative solutions throughout the value chain, helping clients in speeding up drug discovery, enhancing patient care, achieving commercial success, and streamlining product delivery processes.

With a workforce that boasts over 450 AWS-certified experts, Agilisium also provides clients with the opportunity to leverage AWS's Migration Acceleration Program (MAP) funding. This allows organizations to undergo their cloud transformation more seamlessly. Agilisium offers complimentary assessment programs focusing on leveraging cloud technologies.

Conclusion

Agilisium’s distinction by AWS not only validates its approach and strategies, but it also underscores its dedication to pioneering advancements within the Life Sciences domain. For companies looking toward advancement through data and cloud solutions, Agilisium stands ready to lead the way into the future of Life Sciences innovation.

To learn more about their offerings, visit Agilisium’s official site.